✦ LIBER ✦

Results of a double-blind phase 2b study of monthly mimopezil implants compared to oral donepezil in patients with moderate Alzheimer's disease (BRAINZ study)

✍ Scribed by David Wilkinson; Sharon Cohen; Fraser Inglis; Giovanni Marotta; Chris Davis; Jack Kooy; Ziad Nasreddine; Sy Lam; Genevieve Decosterd; Pierre Grosgurin; Herve Porchet; Emmanuel Tamches

Book ID: 118465272
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 45 KB
Volume: 5
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2009.05.218

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter, double-blind, placebo-con

A multicenter, double-blind, placebo-controlled phase IIb proof-of-concept dose-ranging study of AZD3480 and donepezil over 12 weeks in patients with mild to moderate Alzheimer's disease

✍ Lutz Frölich; Göran Eckerwall; Nilsson Jonas 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A multinational, randomised, 12-week stu

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

✍ X. A. Alvarez; R. Cacabelos; M. Laredo; V. Couceiro; C. Sampedro; M. Varela; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Results from CONNECTION: A global, Phase

Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease

✍ Rachelle S. Doody; Pierre Tariot; Jeff Cummings; Bengt Winblad; Bryan Selby; And 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Synergistic treatment effects with Cereb

Synergistic treatment effects with Cerebrolysin and donepezil: Results from a randomized, double-blind, multicenter trial to compare safety and efficacy of Cerebrolysin, donepezil and a combination treatment in patients with probable Alzheimer's disease

✍ Edith Doppler; Anton Alvarez; Ramón Cacabelos; Manuel Aleixandre; Carlos Linares 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 186 KB